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Abstract
Background: A single nucleotide polymorphism (61A>G) in the epidermal growth factor (EGF)
gene has been implicated in both melanoma pathogenesis and increased melanoma risk. To further
evaluate this association, we conducted a case-control study in a clinic-based Italian population.
Methods: Individuals with less than 10 (N = 127) or more than 100 (N = 128) benign nevi, and
patients with cutaneous melanoma (N = 418) were investigated for the EGF  +61A>G
polymorphism, using an automated sequencing approach.
Results: Overall, no difference in EGF genotype frequencies was observed among subjects with
different number of nevi as well as when non-melanoma healthy controls were compared with the
melanoma patients. However, a heterogeneous distribution of the frequencies of the G/G genotype
was detected among cases and controls originating from North Italy (21.1 and 18.3%, respectively)
vs. those from South Italy (12.6 and 17.1%, respectively).
Conclusion: Our findings further suggest that EGF +61A>G polymorphism may have a limited
impact on predisposition and/or pathogenesis of melanoma and its prevalence may vary in different
populations.
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Background
The epidermal growth factor (EGF) gene, which is a mem-
ber of the EGF superfamily, has been demonstrated to
activate cell proliferation and stimulate mitogenesis in
epidermal tissue, enhancing tumour growth [1].
In a previous case-control study conducted in the United
Kingdom, the 61A>G transversion (rs4444903) in the
EGF gene has been correlated with an increased risk of
melanoma in vivo [2]. In particular, the prevalence of the
G/G genotype was significantly higher in melanoma
patients than in healthy individuals as controls (both
originating from northern European countries); the G
allele was present in nearly 66% of patients with malig-
nant melanoma (odds ratio 4.9 [95% CI 2.3–10.2]; p <
0.0001) [2]. Overall, the A and G alleles have been
reported in 56–63% and 37–44%, respectively, of all the
EGF alleles in the European Caucasian populations [2-8].
Among melanoma patients, a significant association with
the Breslow thickness was also inferred (odds ratio 3.7
[95% CI 1.0–13.2]; p = 0.045) [2].
From the biological point of view, it has been hypothe-
sized that presence of the G allele at position 61 of the
EGF gene leads to increased in vitro expression of the EGF
protein (suggesting that such a sequence variant may act
as a functional polymorphism) [2]. Since the original
report, majority of studies conducted in different Cauca-
sian populations have not confirmed such an association
between the EGF +61A>G polymorphism and the predis-
position to melanoma or nevi development [3-6]. Moreo-
ver, conflicting findings have been also reported about the
correlation of such a polymorphism with Breslow thick-
ness and survival prediction [4-7].
Through a case:control study carried out within the entire
Italian population, we here investigated the role of the
EGF  +61A>G polymorphism in nevi formation and
melanoma pathogenesis, in order to further assess
whether the G allele-dependent EGF production might be
important in the development of such a disease.
Methods
About 1,500 individuals underwent a whole-body skin
examination using the epiluminescence microscopy.
Melanocytic nevi were found in the range between 1–9
and 10–100 in about 23% and 68% of the participants,
respectively; about 9% of them had more than 100 benign
melanocytic nevi. One hundred and twenty-seven consec-
utively-collected individuals with low number of benign
melanocytic nevi (<10), 128 subjects with high number of
benign melanocytic nevi (>100), and 418 patients with
histologically-proven diagnosis of cutaneous melanoma
were included into the study. To avoid any bias,
melanoma patients were consecutively collected from Jan-
uary 2003 to December 2005; they were included regard-
less of age at diagnosis, family history status, and disease
features. Histological classification (including Breslow
thickness and Clark level of invasion) was confirmed by
medical records, review of pathologic material, and/or
pathology reports.
Patients were from different Italian regions; non-
melanoma healthy controls aged 21–60 years (either
those with high or those with low nevi numbers) were
chosen as representative of the individuals living in the
same geographical areas and were comparable for sex, age
and general phenotype (hair and eye color, tanning type)
to patients with melanoma. After individuals were
informed about aims and limits of the study, blood sam-
ples were obtained with their written consent. The study
was reviewed and approved by the ethical review boards
of both the Azienda Sanitaria Locale of Sassari-Olbia and
the University of Sassari.
Genomic DNA from all cases and controls was isolated
from peripheral blood, using standard methods, and then
screened for the A>G polymorphism at position 61 of the
5' untranslated region of EGF gene, using an automated
direct sequencing approach. Primers for polymerase chain
reaction (PCR) assays were as previously described [2].
Odds ratios of carrying the EGF +61A>G polymorphism
were estimated by the logistic regression model and
reported with 95% confidence interval (95% CI). Analy-
ses were performed with the statistical package SPSS/7.5
for Windows.
Results and discussion
Figure 1 shows the nucleotide sequences for the three
expected genotypes at position 61 of the EGF  gene:
homozygosity A/A, heterozygosity A/G, homozygosity G/
G.
As shown in Table 1, both the G/G genotype and the G
allele frequencies did not significantly differ according to
the total number of benign nevi. When we compared all
these individuals, who were considered as non-melanoma
healthy controls, with the melanoma cases, again no dif-
ference in EGF  genotype frequencies was observed
between such two groups (Table 2). After adjustment for
age and sex, the G/G genotype was not more common
among melanoma patients compared with healthy sub-
jects (16.3 and 17.6%, respectively; OR, 0.89; 95% CI,
0.29–1.63). Interestingly, a heterogeneous distribution of
the frequencies of the G/G genotype was detected among
cases and controls of different geographical origin. A non-
significant higher prevalence of the G/G genotype was
found among melanoma patients as compared with
healthy subjects originating from North Italy (21.1 andBMC Dermatology 2009, 9:7 http://www.biomedcentral.com/1471-5945/9/7
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Sequencing results for the single nucleotide polymorphism at position 61 of the EGF gene Figure 1
Sequencing results for the single nucleotide polymorphism at position 61 of the EGF gene. Electropherograms 
show the nucleotide sequences corresponding to the three different genotypes; arrows indicate the nucleotide position within 
the sequence.BMC Dermatology 2009, 9:7 http://www.biomedcentral.com/1471-5945/9/7
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18.3%, respectively; OR, 1.39; 95% CI, 0.38–2.77),
whereas an inverse distribution was observed among
melanoma patients as compared with healthy subjects
originating from South Italy (12.6 and 17.1%, respec-
tively; OR, 0.63; 95% CI, 0.22–1.46) (Table 3). Further-
more, there was no evidence that both the G/G genotype
and the G allele were associated with disease progression
[in terms of Breslow depth (median thickness: A/A geno-
type, 0.89 mm; G/G genotype, 0.95 mm) and Clark level
of invasion (the G/G genotype was found in about 17% of
Clark I–II cases, 16% of Clark III cases, and 16% of Clark
IV–V cases)] as well as with presence of ulceration as prog-
nostic factor.
Our findings seem to suggest that the role of genetic fac-
tors in predisposition and/or pathogenesis of melanoma
needs to be evaluated in every different populations and
geographical areas. Although the absence of impact of the
EGF +61A>G polymorphism on either development of
nevi or melanoma susceptibility in Italy is consistent with
data reported in other populations [3-7], an evident dis-
crepancy in prevalence distribution of such a gene
sequence variant was observed among cases originating
from northern and southern Italian regions. This phe-
nomenon may probably due to a different origin and/or
"genetic background" of italian melanoma patients. As for
mutation frequencies of other candidate melanoma genes
[9], these data are further supporting the hypothesis that
genetic factors associated to such a disease may be differ-
ently prevalent in North and South Italy, somehow vary-
ing according to the variation of the population incidence
rates of the disease within these two geographical areas
(roughly, 12 versus 4 new melanoma cases per 100.000
inhabitants per year in North Italy and South Italy, respec-
tively [10]). Finally, our study provides evidence against
the conclusions of previous reports which indicated that
the  EGF  +61A>G polymorphism may be a potential
marker for disease severity, predicting a poorer survival [5-
7]. This represents a further confirmation that genetic fac-
tors modifying melanoma progression might also be geo-
graphically heterogeneous.
Table 1: Prevalence of EGF genotypes and allele frequencies according to total number of nevi.
Genotype <10 total nevi
(%)
>100 total nevi
(%)
A/A 48
(38%)
45
(35%)
A/G 56
(44%)
61
(48%)
G/G 23
(18%)
22
(17%)
Total cases 127 128
Allele
A1 5 2
(60%)
151
(59%)
G1 0 2
(40%)
105
(41%)
Table 2: Prevalence of EGF genotypes and allele frequencies among melanoma and non-melanoma subjects.
Genotype Healthy controls
(%)
Melanoma patients
(%)
Odds ratio*
(95% CI)
A/A 93
(36.5%)
144
(34.4%)
1.00
A/G 117
(45.9%)
206
(49.3%)
1.13
(0.57–2.11)
G/G 45
(17.6%)
68
(16.3%)
0.89
(0.29–1.63)
Total cases 255 418
Allele
A3 0 3
(60%)
494
(59%)
1.00
G2 0 7
(40%)
342
(41%)
1.04
(0.39–1.97)
*adjusted for age and sex. CI, confidence intervalBMC Dermatology 2009, 9:7 http://www.biomedcentral.com/1471-5945/9/7
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Conclusion
The EGF +61A>G polymorphism seems to play a limited
role on either predisposition or pathogenesis of
melanoma; prevalence of such a genetic variant may
deeply vary in different populations.
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